Therapeutics

Aptamer Therapeutics Consulting Group (ATCG) harnesses the Raptamer™ technology to develop novel therapeutic strategies for a variety of diseases such as infectious diseases, autoimmune diseases and cancer. Raptamers™ combine therapeutic advantages of monoclonal antibodies and small molecule drugs, providing high binding affinity and specificity to specific targets while requiring short generation time and low cost for up-scale production. ATCG collaborates with renowned scientists from top-tier research institutes including MDACC, BCM, UCSC, TAMU and UTSW to bring aptamer-based therapeutics from bench to bedside.

Contact us for more information.

ATRAPOS THERAPEUTICS is developing targeted immunomodulatory therapeutics for management of diseases originating from overactive immune responses. The lead molecule has demonstrated encouraging activity in animal models of allergic asthma, and is currently being evaluated in other preclinical therapeutic settings, including pulmonary fibrosis and atopic dermatitis. The company is targeting STAT6 protein, a key nexus in the dysregulation of immune cell-driven allergic diseases. Other targets upstream of STAT6 that contribute to this dysregulation are currently targeted by FDA-approved therapeutics for the treatment of some of these allergic diseases Although STAT6 has been previously identified as an attractive therapeutic target, developing an inhibitor has been challenging. Inhibitory molecules need to incorporate a charge to interact with the target protein, but this same charge inhibits the ability of the potential inhibitors to cross the uncharged cell membrane and engage the protein within. Atrapos’ novel strategy surmounts this obstacle by hiding this charge in an inactive prodrug state; once within the cell, the drug is activated as the charge is revealed.

Contact us for more information.

ALLTERUM THERAPEUTICS is developing a monoclonal antibody therapy for the treatment of pediatric T-cell acute lymphoblastic leukemia.

Contact us for more information.

rHDL THERAPEUTICS is developing a novel nanoparticulate drug delivery platform capable of selectively targeting certain cell types and delivering a therapeutic payload of ribonucleic acids (RNA) for multiple disease indications. The technology harnesses the body’s endogenous cholesterol delivery mechanisms by artificially reconstituting high-density lipoproteins (HDL). Published and preliminary data demonstrate that the rHDL particles are protected from the body’s natural defense mechanisms, exhibit prolonged circulation time, and are generally non-toxic in humans. It has been used to successfully deliver therapeutic amounts of genetic material to cancer cells, both in vitro and in vivo. The technology is being developed through a scientific partnership with teams from MD Anderson Cancer Center and University of North Texas Health Science Center.

Contact us for more information.